



FY 2007

SYNGENE & BRISTOL MYERS SQUIBB

A SYMBIOTIC GLOBAL PARTNERSHIP

Long term research services partnership to help advance Bristol-Myers Squibb's discovery and early drug development

Focus on integrated capabilities in medicinal chemistry, biology, drug metabolism and pharmaceutical development.

Leveraging the current global demand for bio-partnering, this alliance aims to provide BMS cost-effective growth and access to top scientific talent in India

Dedicated, 150,000 sq ft. facility to house more than 400 scientists

SYNGENE & BRISTOL MYERS SQUIBB

A SYMBIOTIC GLOBAL PARTNERSHIP



NEPHROLOGY DIVISION

A COMPREHENSIVE PORTFOLIO OF RENAL PRODUCTS

Biocon's new Nephrology Division offers a comprehensive portfolio of renal therapy products.

The new immunosuppressants for renal therapy include RENODAPT (mycophenolate mofetil), TACROGRAF (tacrolimus), CYCLOPHIL ME (cyclosporine micro-emulsion USP), RAPACAN (sirolimus) and ERYPRO (r-hu-EPO).

Immunosuppressants are powerful inhibitors of the body's immune system and are used to prevent allograft rejection

Biocon is the largest vertically integrated manufacturer of immunosuppressants in India with US-FDA approved API facilities

NEPHROLOGY DIVISION

A COMPREHENSIVE PORTFOLIO OF RENAL PRODUCTS

RENPODAPT, CYCLOPHIL ME , TACROGRAF are immunosuppressants for Nephrotic syndrome and kidney transplant

RAPACAN- for chronic allograft nephropathy

ERYPRO - for anaemia management in renally impaired patients



BIOCON PARK COMMENCES OPERATIONS

RECEIVES USFDA NOD

Dr. A P J Abdul Kalam, President of India, inaugurated India's largest integrated biotech hub, "Biocon Park".

API manufacturing facilities at Biocon Park successfully commissioned

Facilities inspected by USFDA and certified to be in compliance to international regulatory standards

Exports to global markets commence

AN INTEGRATED BIOPHARMACEUTICAL HUB




Syngene

*Biocon
Biopharmaceuticals*

**BIOCON
PARK**



Biocon Park building global scale



BIOMAb-EGFR™



NEW PARADIGM IN HEAD & NECK CANCERS

Very successful launch and acceptance in India of Biocon's novel monoclonal antibody, BIOMAb-EGFR™

First *humanized* anti-EGFR monoclonal antibody commercialized anywhere in the world

Approved for use in SCCHN (head & neck cancer) and being evaluated in global clinical trials for colorectal, lung, brain (glioma) and pancreatic cancers.

Indigenous clinical development and manufacture enables affordable treatment in relation to global equivalents

Manufacturing facility in partnership with CIMAB, Cuba

Will target market expansion into SAARC and GCC region in future

LEVERAGING COST & INNOVATION TO DELIVER AFFORDABILITY



**Biocon's first
onco-therapeutic**

presenting

BIOMAb EGFR™

TARGETS CANCER, EXTENDS LIFE

Developed an affordable antibody for Indian cancer patients





OTHER CORPORATE DEVELOPMENTS

Branded formulations business shows good growth and geographic penetration

Biocon and Abu Dhabi's NMC Group sign MOU to manufacture and market bio-pharmaceuticals in the Gulf region (GCC).

Biocon establishes strategic relationships to take insulin to global markets

Biocon and its partner, Bentley Pharmaceuticals, received approval to initiate Phase II clinical studies in India for intranasal insulin; will supplement trial underway in USA

OTHER CORPORATE DEVELOPMENTS

Biocon continues to invest significantly in R&D

Oral insulin program progresses; on track to enter Phase II trials later this year

Other R&D programs on bio-similar proteins and monoclonal antibodies progress up the development path



Financial Highlights

FY 2007

Performance Highlights : FY 07

Revenues **Rs. 990 crs** PAT **Rs. 200 crs**

- Total Income higher by 25% over previous year.
- Operating margins at 29%.
- PAT margins at 20%.
- Research and Licensing Income grew 63%.
- Board recommends Dividend @ 60% (Rs 3 per share).

P & L : FY 07 vs FY 06

(Rs. Cr)

| Particulars | FY - 07 | % on Revenues | FY - 06 | % on Revenues |
|-------------|---------|---------------|---------|---------------|
| Revenues | 990 | | 793 | |
| EBIDTA | 287 | 29% | 234 | 29% |
| PBT # | 217 | 22% | 205 | 26% |
| Tax | 17 | 2% | 31 | 4% |
| PAT | 200 | 20% | 174 | 22% |

after Minority interest


P & L : Q-4 FY 07 vs Q-4 FY 06 (Rs. Cr)

| Particulars | Q4 - 07 | % on Revenues | Q4 - 06 | % on Revenues |
|-------------|---------|------------------|---------|------------------|
| Revenues | 279 | | 215 | |
| EBIDTA | 87 | 31% | 61 | 28% |
| PBT # | 67 | 24% | 53 | 24% |
| Tax | 7 | 2% | 5 | 2% |
| PAT | 61 | 22% | 48 | 22% |

after Minority interest

Revenue (Segment wise)

(Rs. Cr)



THANK YOU